Fuan Pharmaceutical Group Co
Fuan Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, research and develops, produces, and sells chemical drugs in the People's Republic of China. It offers APIs; intermediates; and FFPs, such as anti-tumor, generic drugs, antibiotics and oral, as well as freeze-drying preparation for injection. The company was formerly known as Chongqing Fuan Pharmaceutical (Group) Co., Ltd. and… Read more
Fuan Pharmaceutical Group Co (300194) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.023x
Based on the latest financial reports, Fuan Pharmaceutical Group Co (300194) has a cash flow conversion efficiency ratio of 0.023x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥100.27 Million) by net assets (CN¥4.45 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Fuan Pharmaceutical Group Co - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Fuan Pharmaceutical Group Co's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Fuan Pharmaceutical Group Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fuan Pharmaceutical Group Co ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hagerty Inc
NYSE:HGTY
|
0.129x |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
-0.127x |
|
Xinjiang Baodi Mining Co. Ltd. A
SHG:601121
|
N/A |
|
ITOCHU ENEX
F:96P
|
N/A |
|
momo.com Inc
TW:8454
|
0.213x |
|
EcoRodovias Infraestrutura e Logística S.A
SA:ECOR3
|
0.312x |
|
NMDC Steel Limited
NSE:NSLNISP
|
0.035x |
|
Hippo Holdings Inc
NYSE:HIPO
|
0.040x |
Annual Cash Flow Conversion Efficiency for Fuan Pharmaceutical Group Co (2007–2024)
The table below shows the annual cash flow conversion efficiency of Fuan Pharmaceutical Group Co from 2007 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥4.40 Billion | CN¥303.59 Million | 0.069x | -12.95% |
| 2023-12-31 | CN¥4.15 Billion | CN¥328.98 Million | 0.079x | -7.82% |
| 2022-12-31 | CN¥3.95 Billion | CN¥339.50 Million | 0.086x | +29.34% |
| 2021-12-31 | CN¥3.87 Billion | CN¥257.13 Million | 0.067x | +86.38% |
| 2020-12-31 | CN¥4.56 Billion | CN¥162.55 Million | 0.036x | -51.84% |
| 2019-12-31 | CN¥3.99 Billion | CN¥295.63 Million | 0.074x | +2.27% |
| 2018-12-31 | CN¥3.69 Billion | CN¥267.68 Million | 0.072x | -33.34% |
| 2017-12-31 | CN¥4.17 Billion | CN¥453.37 Million | 0.109x | +15.16% |
| 2016-12-31 | CN¥3.96 Billion | CN¥374.16 Million | 0.094x | +25.23% |
| 2015-12-31 | CN¥2.14 Billion | CN¥161.03 Million | 0.075x | +511.64% |
| 2014-12-31 | CN¥1.71 Billion | CN¥-31.27 Million | -0.018x | -135.25% |
| 2013-12-31 | CN¥1.72 Billion | CN¥89.61 Million | 0.052x | +42.41% |
| 2012-12-31 | CN¥1.72 Billion | CN¥62.77 Million | 0.036x | -4.80% |
| 2011-12-31 | CN¥1.69 Billion | CN¥64.85 Million | 0.038x | -89.82% |
| 2010-12-31 | CN¥281.05 Million | CN¥105.74 Million | 0.376x | -2.08% |
| 2009-12-31 | CN¥163.31 Million | CN¥62.75 Million | 0.384x | -13.55% |
| 2008-12-31 | CN¥110.76 Million | CN¥49.23 Million | 0.444x | -80.47% |
| 2007-12-31 | CN¥8.31 Million | CN¥18.92 Million | 2.276x | -- |